Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Nurr1 as a genetic target for treating levodopa-induced dyskinesias in Parkinson's disease

Nurr1 as a genetic target for treating levodopa-induced dyskinesias in Parkinson's disease

US Patent 10144932 · Granted Dec 4, 2018

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination serotonin specific reuptake inhibitor and serotonin 1A receptor part2025
Sprr1A as a genetic target for treating neurodegenerative diseases2022
Sprr1A as a genetic target for treating neurodegenerative diseases2022
Sprr1A as a genetic target for treating neurodegenerative diseases2022
Predicting therapeutic response in Parkinson's disease2022
Predicting therapeutic response in Parkinson's disease2022
Composition and method for preventing or treating a tauopathy2018
Composition and method for treating a tauopathy2017
Use of pleiotrophin to promote neurogeneration2009
Erythropoietin administration to improve graft survival2008
Erythropoietin administration to improve graft survival2008
Dopaminergic neurotrophic factor for treatment of Parkinson's disease1993